Sign Out
There are no studies in pregnant women using Capecitabine (Xeltabine).
In reproductive toxicity studies in animals, Capecitabine (Xeltabine) administration caused embryolethality and teratogenicity. These findings are expected effects of fluoropyrimidine derivatives. As taking Capecitabine (Xeltabine) during pregnancy can damage fetus, Capecitabine (Xeltabine) should be considered as possible inducer of teratogenicity. Therefore Capecitabine (Xeltabine) is contraindicated during pregnancy. If this drug is used during pregnancy, or if a patient becomes pregnant while receiving Capecitabine (Xeltabine), the patient should be apprised of the potential hazard to the fetus.
Men and women should use birth control while taking Xeltabine.
It is not known whether Capecitabine (Xeltabine) is excreted in human breast milk. In lactating mice, considerable amounts of Capecitabine (Xeltabine) and its metabolites were found in milk. Breast-feeding should be discontinued while receiving treatment with Capecitabine (Xeltabine).
Continue with Google